MVIR:STO
Medivir AB
SEK 1.48
arrow_downward
-0.94%(-0.014) 1 天
10月12日, GMT+2 15:57:03 · SEK
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 MVIR 生成关键数据洞见…
开盘价
SEK 1.49
最高价
SEK 1.51
最低价
SEK 1.46
市值
9.26亿
平均成交量
145.17万
成交量
135.54万
52 周最高价
SEK 2.88
52 周最低价
SEK 0.34
每股收益
-SEK 0.37
流通股数
6.24亿
员工人数
6
开盘价
SEK 1.49
最高价
SEK 1.51
最低价
SEK 1.46
市值
9.26亿
平均成交量
145.17万
成交量
135.54万
52 周最高价
SEK 2.88
52 周最低价
SEK 0.34
每股收益
-SEK 0.37
流通股数
6.24亿
员工人数
6
新闻报道
来自网络来源和新闻合作伙伴
www.tmgm.com
·
4小时前
标普500：盈利强劲抵消收益率逆风——HSBC
Traders Union
·
16小时前
Ryan Detrick指出，S&P 500自2019年以来的涨幅主要由盈利和股息推动
www.me.news
·
5小时前
大摩研报解读：标普等权重跌 5%，AI 集中度风险在年末前积累
资料
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Medivir AB简介